




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/40, 31/35		A1	(11) International Publication Number: WO 94/20098
			(43) International Publication Date: 15 September 1994 (15.09.94)
(21) International Application Number: PCT/US94/00633		(81) Designated States: AU, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, NO, NZ, PL, RO, RU, SK, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 13 January 1994 (13.01.94)			
(30) Priority Data: 08/029,729 11 March 1993 (11.03.93) US		Published With international search report.	
(71) Applicant: ZYMOGENETICS, INC. [US/US]; 4225 Roosevelt Way N.E., Seattle, WA 98105 (US).			
(72) Inventors: LABROO, Virender, M.; 2814 163rd Place S.E., Mill Creek, WA 98012 (US). PIGGOTT, James, R.; 23612 Meridian Avenue West, Bothell, WA 98021 (US). BAIN, Steven, D.; 123 NW 180th, Seattle, WA 98177 (US).			
(74) Agent: PARKER, Gary, E.; Zymogenetics, Inc., 4225 Roosevelt Way N.E., Seattle, WA 98105 (US).			

(54) Title: METHODS FOR INHIBITING BONE LOSS WITH 3,4-DIARYLCHROMAN

a=significantly decreased vs ovx/E2 and ovx/C groups; $P < .05$.b=significantly decreased vs sham and ovx/E2 groups; $P < .01$.

(57) Abstract

Methods and pharmaceutical compositions for reducing bone loss are disclosed. 3,4-diarylchromans and their pharmaceutically acceptable salts are formulated into medicaments for the treatment of bone loss due to osteoporosis or other conditions. An exemplary 3,4-diarylchroman is centchroman (3,4-*trans*-2,2-dimethyl-3-phenyl-4-[*p*-(beta-pyrrolidinoethoxy) phenyl]-7-methoxy-chroman). Formulations include tablets and other forms suitable for oral administration and controlled-release subdermal implants.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

METHODS FOR INHIBITING BONE LOSS WITH
3,4-DIARYLCHROMAN

Background of the Invention

5 Bone remodeling is the dynamic process whereby skeletal mass and architecture are renewed and maintained. This renewal and maintenance is a balance between bone resorption and bone formation, with the osteoclast and the osteoblast considered the two key participants in the
10 remodeling process. The osteoclast initiates the remodeling cycle by resorbing a cavity in the bone which is subsequently refilled when the osteoblast synthesizes and deposits new bone matrix into the excavation. The activities of osteoclast and osteoblast are regulated by
15 complex interactions between systemic hormones and the local production of growth factors and cytokines at active remodeling sites.

 Imbalances in bone remodeling are associated with such conditions as osteoporosis, Paget's disease, and
20 hyperparathyroidism. Osteoporosis, characterized by a decrease in the skeletal mass, is one of the most common diseases of postmenopausal women and is often the cause of debilitating and painful fractures of the spine, hip and wrist.

25 Approximately 25% of all postmenopausal women suffer from osteoporosis, and it is generally accepted that the etiology of the disease involves the reduction of circulating estrogens (Komm et al., Science 241:81-84, 1988). Komm et al. further report that the proportion of
30 caucasian women in the United States who are at risk for a hip fracture is 15%, or 247,000 hip fractures per year in women over the age of 45.

 The costs of osteoporosis, both personal and financial, are enormous. In 1984, 145,000 in-patient
35 fracture reductions and 107,000 hip arthroplasties and replacements were performed on American women over 65

- 2 -

years of age. Among patients who lived alone prior to hip fracture, 15% to 20% required long-term care as a result of the fracture and one year after the fracture had still not regained their independence. The total financial cost of osteoporosis treatment, including fractures, in the United States in 1986 was 7-10 billion dollars (Peck et al., Am. J. Med. 84:275-282, 1988).

Bone loss associated with osteoporosis has been arrested by the administration of exogeneous estrogens. To be effective, estrogen therapy must begin within a few years of the onset of menopause, and should continue for 10 to 15 years, according to Thorneycroft (Am. J. Obstet. Gynecol. 160:1306-1310, 1989). While there are several different types of estrogens, 17- β -estradiol is the primary estrogen found naturally occurring in premenopausal women and is often the compound of choice for therapeutic use. At the recommended dose, however, there are significant side effects, the most disturbing being the well-established correlation of estrogen therapy with endometrial and breast cancers. The incidence of carcinoma is both dose-dependent and duration-dependent.

Avoidance of the cancer risk has been achieved by the concomitant use of a progestogen with estrogen. This combination, however, causes menses to return, which many women find unacceptable. A further disadvantage is that the long-term effects of the progestogen have not been fully determined. Thus, a large population of women require alternatives to hormone replacement therapies that can safely prevent the rapid bone loss that accompanies the menopause.

Centchroman is a non-steroidal compound known to have antiestrogenic activity. It is in use in India as an oral contraceptive (see, for example, Salman et al., U.S. Patent No. 4,447,622; Singh et al., Acta Endocrinol (Copenh) 126:444-450, 1992; Grubb, Curr. Opin. Obstet. Gynecol. 3:491-495, 1991; Sankaran et al., Contraception

- 3 -

9:279-289, 1974; Indian Patent No. 129187). Centchroman has also been investigated as an anti-cancer agent for treatment of advanced breast cancer (Misra et al., Int. J. Cancer 43:781-783, 1989), but has not previously been shown to have an effect on bone resorption.

There remains a need in the art for compositions and methods useful in reducing bone loss, in particular bone loss associated with osteoporosis. There is a further need for such compositions that lack the undersirable side effects of estrogens. The present invention provides such compositions and methods and also provides other, related advantages.

Brief Description of the Drawings

Figure 1 illustrates the effects of centchroman on bone loss in ovariectomized mice.

Figure 2 illustrates the effects of centchroman on cancellous bone volumes in the proximal tibiae of ovariectomized rats.

Figure 3 illustrates the effects of centchroman on bone resorption (left) and uterine weights (right) in ovariectomized rats.


Detailed Description of the Invention

The present invention is based in part on the discovery that a representative 3,4-diarylchroman, centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-[p-(beta-pyrrolidinoethoxy)phenyl]-7-methoxy-chroman), is an effective inhibitor of bone loss in ovariectomized mice and rats. These animal models mimic the post-menopausal condition and are generally recognized models of osteoporosis. These data thus indicate that the 3,4-diarylchromans are useful as therapeutic agents for reducing bone loss in mammals, including primates such as humans.

- 4 -

Within the present invention, compounds of formula (I) or their pharmaceutically acceptable salts are used for reducing bone loss in a patient.

5



(I)

10

Within formula (I), R1, R4 and R5 are individually hydrogen, halo, trifluoromethyl, lower alkyl, lower alkoxy or tertiary amino lower alkoxy; and R2 and R3 are individually H or a lower alkyl. As used herein, the term "lower alkyl" includes straight and branched chain alkyl radicals containing from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-amyl, sec-amyl, n-hexyl, 2-ethylbutyl, 2,3-dimethylbutyl and the like. The term "lower alkoxy" includes straight and branched chain alkoxy radicals containing from 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, n-amxyloxy, sec-amxyloxy, n-hexyloxy, 2-ethyl-butoxy, 2,3-dimethylbutoxy and the like. "Halo" includes chloro, fluoro, bromo and iodo. The tertiary amino radical may be a dialkylamine such as a dimethyl, diethyl, dipropyl, dibutyl or a polymethyleneimine, e.g. piperidine, pyrrolidine, N-methyl piperazine or morpholine. Preferred compounds include those in which R1 is lower alkoxy; R2 and R3 are lower alkyl, especially methyl; R4 is H; and R5 is tertiary amino lower alkoxy of the polymethyleneimine


30

- 5 -

type. Within particularly preferred embodiments, R1 is in the 7-position and is lower alkoxy, particularly methoxy; each of R2 and R3 is methyl, R4 is H and R5 is in the 4-position and is a tertiary amino lower alkoxy radical such as pyrrolidinoethoxy.

It is preferred to use the compounds of structure (I) in the *trans* configuration. These compounds may be used as racemic mixtures, or the isolated *d*- or *l*-enantiomers may be used.

A particularly preferred compound for use within the present invention is centchroman (II):



15

Although only one enantiomer is shown, it will be understood that the structure II is used herein to designate the *trans* configuration of the 3- and 4-phenyl groups and that both the *d*- and *l*-enantiomers, as well as the racemic mixture, are included.

3,4-diarylchromans are prepared according to known methods, such as those disclosed in U.S. Patent No. 3,340,276 to Carney et al., U.S. Patent No. 3,822,287 to Bolger, and Ray et al., *J. Med. Chem.* 19:276-279, 1976, which are incorporated herein by reference. Conversion of the *cis* isomer to the *trans* configuration by means of an

- 6 -

organometallic base-catalyzed rearrangement is disclosed in U.S. Patent No. 3,822,287. The optically active *d*- and *l*- enantiomers may be prepared as disclosed by Salman et al. in U.S. Patent No. 4,447,622 (incorporated herein by reference) by forming an optically active acid salt which is subjected to alkaline hydrolysis to produce the desired enantiomer.

Within the present invention, 3,4-diarylchromans may be prepared in the form of pharmaceutically acceptable salts, especially acid-addition salts, including salts of organic acids and mineral acids. Examples of such salts include salts of organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid and the like. Suitable inorganic acid-addition salts include salts of hydrochloric, hydrobromic, sulfuric and phosphoric acids and the like. The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.

3,4-diarylchromans and their salts are useful within human and veterinary medicine for the regulation of bone metabolism. These compounds may be used, for example, in the treatment of patients suffering from bone loss due to osteoporosis (including post-menopausal osteoporosis and glucocorticoid-related osteoporosis), Paget's disease, hyperparathyroidism, hypercalcemia of malignancy and other conditions characterized by excessive rates of bone resorption and/or decreased rates of bone formation.

For use within the present invention, 3,4-diarylchromans and their pharmaceutically acceptable salts are formulated with a pharmaceutically acceptable carrier

- 7 -

to provide a medicament for parenteral, oral, nasal, rectal, subdermal or transdermal administration according to conventional methods. Formulations may further include one or more diluents, fillers, emulsifiers, preservatives, buffers, excipients, etc. and may be provided in such forms as liquids, powders, emulsions, suppositories, liposomes, transdermal patches, controlled release subdermal implants, tablets, etc. One skilled in this art may formulate the compounds in an appropriate manner, and in accordance with accepted practices, such as those disclosed in Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton, PA, 1990 (which is incorporated herein by reference in its entirety.)

Oral administration is preferred. Thus, the active compound is prepared in a form suitable for oral administration, such as a tablet or capsule. Typically, a pharmaceutically acceptable salt of the compound is combined with a carrier and molded into a tablet. Suitable carriers in this regard include starch, sugars, dicalcium phosphate, calcium stearate, magnesium stearate and the like. Such compositions may further include one or more auxiliary substances, such as wetting agents, emulsifiers, preservatives, stabilizers, coloring, etc.

Pharmaceutical compositions are administered at daily to weekly intervals. An "effective amount" of such a pharmaceutical composition is the amount that provides a clinically significant inhibition of bone loss. Such amounts will depend, in part, on the particular condition to be treated, age, weight, and general health of the patient, and other factors evident to those skilled in the art. In general, inhibition of bone loss is manifested as a statistically significant difference in cancellous bone volume between treatment and control groups. This can be seen as, for example, a 5-10% or more difference in spinal bone mass or bone mineral content over two years. Data from accepted animal models, such as the ovariectomized

- 8 -

mouse or rat models of osteoporosis, are generally predictive of doses in humans to within one order of magnitude. For example, therapeutic doses for the treatment of osteoporosis will generally range from 0.01-50 mg/kg/day, preferably 0.05-10 mg/kg/day, most preferably 0.1-5.0 mg/kg/day. The use of *cis*-isomers or racemic mixtures may necessitate doses in the higher end of the stated range.

The pharmaceutical compositions may be administered in unit dosage form on a daily to weekly basis. In the alternative, they may be provided as controlled release formulations suitable for subdermal implantation. Implants are formulated to provide release of active compound over the desired period of time, which can be up to several years. Controlled-release formulations are disclosed by, for example, Sanders et al., J. Pharm. Sci. 73: 1294-1297, 1984; U.S. Patent No. 4,489,056; and U.S. Patent No. 4,210,644, which are incorporated herein by reference.

The following examples are offered by way of illustration, not limitation.

Example 1

The ability of centchroman to prevent osteopenia induced by estrogen deficiency was evaluated in the ovariectomized mouse model. Twenty-four female Swiss-Webster mice (8 weeks old) received either an ovariectomy or sham surgery prior to the initiation of a 4 week treatment protocol. For the ovariectomy, a flank incision through the skin, muscle and abdominal peritoneum was made on each side, the ovaries were located and dissected free of adherent fat and connective tissue, and excised. In the sham procedure the ovaries were exteriorized and replaced. In all animals the peritoneum and muscle were

- 9 -

sutured together and the skin incisions were closed with wound clips.

Centchroman was dissolved in a minimal amount of dimethylsulfoxide and diluted in oil vehicle to a concentration of 50 $\mu\text{g}/100 \mu\text{l}$. The mice were treated twice per week for 4 weeks with a subcutaneous injection of centchroman or oil vehicle according to the following outline: Sham/oil vehicle (SV); OVX/oil vehicle; OVX/50 μg centchroman two times per week. There were 8 animals in each group.

At the conclusion of the 4-week centchroman treatment, the mice were anesthetized with ether and sacrificed by cervical dislocation. Immediately after sacrifice, the femurs were removed and fixed in 70% ethyl alcohol (EtOH) and dehydrated in a series of increasing alcohol concentrations: 95% EtOH for 24 hours followed by three changes in 100% EtOH of 24 hours each. After the final 100% EtOH the femurs were cleared in two changes of xylene and then processed undecalcified and embedded in methacrylate plastic according to previously described methods (Bain et al., Stain Technology 65: 159-163, 1990). Frontal sections of the distal metaphyses of the femur 5 μm thick were cut on a Reichert-Jung 2050 rotary microtome equipped with a tungsten-carbide knife. The 5 μm sections were mounted on glass slides and stained with Goldner's trichrome stain.

Histomorphometric measurements of the distal metaphyses were determined using the Bioquant Bone Morphometry Program (Biometrics, Inc., Nashville, TN) interfaced via a camera lucida with an Olympus BH-2 light/epifluorescent microscope (Scientific Instruments, Inc., Redmond, WA). Morphometric measurements of cancellous bone volume (BV/TV) were performed in the tissue space greater than 0.25 mm from the growth plate-metaphyseal junction to exclude primary spongiosa.

- 10 -

Inc., Redmond, WA). Morphometric measurements of cancellous bone volume (BV/TV) were performed in the tissue space greater than 0.25 mm from the growth plate-metaphyseal junction to exclude primary spongiosa.

5 Data, shown in Figure 1, are expressed as the mean \pm SD for each group. Comparison of cancellous bone volumes of the distal femur were based on analysis of variance using Statview® statistical programs (Abacus Concepts, Inc., Berkeley, CA). Treatment differences
10 indicated by the ANOVA were compared using Dunnett's multiple comparison procedure. A P value of less than .05 was considered significant.

In ovariectomized mice treated with oil vehicle a 50% decrease in the cancellous bone volume of the distal
15 femur compared to sham animals treated with vehicle was observed. In the ovariectomized animals treated with 50 μ g of centchroman twice per week this bone loss was completely prevented.

20 Example 2

To evaluate centchroman effects on bone resorption and bone mass, the skeletons of 54 female Sprague-Dawley rats were pre-labeled over four consecutive weeks with tritiated tetracycline ($^3\text{H-T}$; obtained from
25 Dupont NEN Research Products, Boston, MA). Animals were given 12-15 injections of 15 μCi each for a total of approximately 200 μCi per animal. Three days after the final $^3\text{H-T}$ injection, eight animals were sacrificed as baseline controls, and the remaining animals were
30 randomized for estrogen (E2) or centchroman (C) treatments according to the following outline: sham/placebo; ovariectomy(ovx)/placebo; ovariectomy/E2 (0.05 mg/kg/day); ovariectomy/C (0.05 mg/kg/day); ovariectomy/C (0.5 mg/kg/day); and ovariectomy/C (5.0 mg/kg/day). The
35 hormone treatments were delivered via subcutaneous pellet implants containing a matrix of cholesterol, lactose,

- 11 -

femurs and vertebrae were also determined to document changes in bone physical properties, and quantitative histomorphometry was used to compare changes in cancellous bone volumes of the proximal tibiae.

5 Sixty days after the initiation of the treatment protocols, the animals were anesthetized with ether and sacrificed by cervical dislocation. Immediately after sacrifice, the uteri were removed and weights recorded; both femurs and three thoracic vertebrae (T11-T13) were
10 excised for the bone resorption assay; one tibia and the first lumbar vertebra were collected for determination of bone physical properties; and the second tibia was excised and processed for bone histomorphometry. All tissues were fixed initially in 70% ethyl alcohol (EtOH) and dehydrated
15 in an ascending series of EtOH to 100%. After the final change of 100% EtOH, the specimens were processed according to the assay protocols outlined below.

 The assay of whole bone resorption was based on the levels of $^3\text{H-T}$ retained in the pre-labeled femurs and
20 vertebrae essentially as disclosed by Klein and Jackman (Calcified Tissue Research 20: 275-290, 1976). Briefly, the samples were defatted in three changes of chloroform of 24 hours each and dried at 100°C for 24 hours, and the weights were recorded. To extract the $^3\text{H-T}$, the femurs
25 and vertebrae were demineralized in 15 ml of 0.5 N hydrochloric acid (HCl), and the supernatants were decanted and reserved. To quantify tritium levels, 625 μl aliquots were pipetted into glass scintillation vials containing 10 ml of Optiflor scintillation fluid (Packard
30 Instruments, Meriden, CT), and the $^3\text{H-T}$ levels were counted on a liquid scintillation spectrometer (Beckman LS 1800).

 Following the EtOH dehydration, the samples for measuring bone mass were defatted in three changes of
35 chloroform of 24 hours each and dried in a 60°C oven

- 12 -

overnight. Bone mass was expressed as mg of dry weight per gram of body weight.

After the final 100% EtOH treatment, the tibiae were cleared in two changes of xylene, processed undecalcified and embedded in methacrylate plastic essentially as disclosed by Bain et al. (Stain Technology 65: 159-163, 1990). Frontal sections of the proximal tibiae 5 μ m thick were cut on a Reichert-Jung 2050 rotary microtome (Leica Instruments, Nusslock, Germany) equipped with a tungsten carbide knife. The 5 μ m sections were stained with Goldner's trichrome stain.

Histomorphometric measurements of the proximal tibiae were determined using a Bioquant Bone Morphometry program (Biometrics, Inc., Nashville, TN) interfaced via a camera lucida with an Olympus BH-2 light/epifluorescent microscope (Scientific Instruments, Inc., Redmond, WA). Morphometric measurements of cancellous bone volume (cn.BV/TV) were performed in a 3.0 mm² tissue space 1.5 millimeters from the growth plate-metaphyseal junction to exclude measurements of primary spongiosa. A minimum of four separate sections were measured from each animal.

Analyses of uterine weights, bone resorption assays, bone physical properties and bone histomorphometry were based on analysis of variance (ANOVA) using Statview® statistical programs (Abacus Concepts, Inc., Berkeley, CA). When significance was indicated by the ANOVA, control and treatment means were compared using Dunnett's multiple comparison procedure. P values of less than 0.05 were considered significant.

Compared to sham-vehicle treated animals, ovariectomy led to significant decreases in uterine wet weights. Estrogen replacement restored uterine weights to sham values, but centchroman treatment had no statistically significant effect on uterine weight, even at the highest dose of 5.0 mg per day. Indicative of increased bone resorption, ovariectomy reduced the

- 13 -

skeletal retention of $^3\text{H-T}$ in femurs and vertebrae (Tables 1 and 2, respectively). As expected, estrogen treatment increased the skeletal retention of $^3\text{H-T}$. Centchroman mimicked the effect of estrogen on bone resorption by causing a dose-dependent increase in the skeletal retention of $^3\text{H-T}$ at both skeletal sites (r^2 values equal 0.96 and 0.92 for femora and vertebrae, respectively).

Table 1
Retention of $^3\text{H-T}$ in Femurs

Group	Count	cpm (thousands)	
		Mean	Std. Dev.
sham/placebo	8	3832.25	928.975
ovx/placebo	8	3184.375	680.598
ovx/0.05 mg E2	10	4782	1501.813
ovx/0.05 mg C	9	3373.556	733.896
ovx/0.5 mg C	10	3405.1	1107.792
ovx/5.0 mg C	9	4192.222	1107.3

Table 2
Retention of $^3\text{H-T}$ in Vertebrae

Group	Count	cpm (thousands)	
		Mean	Std. Dev.
sham/placebo	8	1876.75	481.552
ovx/placebo	8	1531.625	416.205
ovx/0.05 mg E2	9	2467.556	733.064
ovx/0.05 mg C	9	1523.333	406.635
ovx/0.5 mg C	10	1616	509.954
ovx/5.0 mg C	10	2156.7	495.741

The ability of centchroman to inhibit bone resorption and prevent bone loss was confirmed by measurements of cancellous bone volume in the tibiae and bone mass determinations of femora and vertebrae. Compared to ovariectomized rats treated with vehicle, centchroman caused a dose-dependent increase in cancellous bone volume of the proximal tibiae (Figure 2; $r^2 = 0.99$). Similarly, centchroman had dose-dependent effects on bone mass in femora and vertebrae.

In summary, these data indicate that the ability of centchroman to prevent bone loss in the ovariectomized

- 14 -


rat is independent of any apparent uterotrophic activity.
This is clearly demonstrated in Figure 3 by combining
uterine weight data with the bone resorption data from the
femur to show the independent effects of centchroman on
5 these two tissues.

Although the foregoing invention has been
described in some detail by way of illustration and
example for purposes of clarity of understanding, it will
10 be evident that certain changes and modifications may be
practiced within the scope of the appended claims.

- 15 -

We claim:

1. A method for reducing bone loss in a patient comprising administering to a patient suffering from bone loss due to osteoporosis, Paget's disease or hyperparathyroidism an effective amount of a composition comprising a bone loss inhibiting compound of the formula



10

or a pharmaceutically acceptable salt thereof, wherein

R1, R4 and R5 are individually hydrogen, hydroxy, halo, trifluoromethyl, lower alkyl, lower alkoxy or tertiary amino lower alkoxy; and

15

R2 and R3 are individually hydrogen or lower alkyl,

in combination with a pharmaceutically acceptable carrier.

20

2. A method according to claim 1 wherein R1 is lower alkoxy, R2 and R3 are lower alkyl, R4 is hydrogen and R5 is tertiary amino lower alkoxy.

25

3. A method according to claim 1 wherein R1 is methoxy.

4. A method according to claim 1 wherein R2 and R3 are methyl.

30

5. A method according to claim 1 wherein R4 is hydrogen.

- 16 -


6. A method according to claim 1 wherein R5 is



5


7. A method according to claim 1 wherein said compound is an isolated *d*- or *l*-enantiomer.

8. A method according to claim 1 wherein said compound is



9. A method according to claim 1 wherein said compound is

15



10. A method according to claim 9 wherein said compound is an isolated *d*- or *l*-enantiomer.

20

- 17 -

11. A method according to claim 1 wherein said patient is a post-menopausal female.


12. A method according to claim 1 wherein said composition is in a form suitable for oral administration.

13. A method according to claim 1 wherein said compound is administered at a dose of 0.1-5.0 mg/kg patient weight/day.

14. A method according to claim 1 wherein said composition is administered at daily to weekly intervals.

15. A method according to claim 1 wherein said composition is in the form of a subdermal implant.

16. A method for treating osteoporosis comprising administering to a patient an isolated *d*- or *l*-enantiomer of a bone loss inhibiting compound of the formula



or a pharmaceutically acceptable salt thereof, wherein

R1, R4 and R5 are individually hydrogen, hydroxy, halo, trifluoromethyl, lower alkyl, lower alkoxy or tertiary amino lower alkoxy; and

R2 and R3 are individually hydrogen or lower alkyl,

in an amount sufficient to inhibit bone resorption.

17. A method according to claim 16 wherein R1 is lower alkoxy, R2 and R3 are lower alkyl, R4 is hydrogen and R5 is tertiary amino lower alkoxy.

5

18. A method according to claim 16 wherein R1 is methoxy.

19. A method according to claim 16 wherein R2 and R3 are methyl.

10

20. A method according to claim 16 wherein R4 is hydrogen.


21. A method according to claim 16 wherein R5 is

15




22. A method according to claim 16 wherein said compound is

20



23. A method according to claim 16 wherein said compound is




5

24. A method according to claim 16 wherein said patient is a post-menopausal female.

25. Use of a compound of the formula

10




for the preparation of a pharmaceutical composition for the treatment of bone loss due to osteoporosis, Paget's disease or hyperparathyroidism, wherein:

15 R₁, R₄ and R₅ are individually hydrogen, hydroxy, halo, trifluoromethyl, lower alkyl, lower alkoxy or tertiary amino lower alkoxy; and

R₂ and R₃ are individually hydrogen or lower alkyl.

1/3



*P<.05 decreased compared to sham animals treated with vehicle and ovx mice treated with centchroman; n = 8 mice/group.

Figure 1

2/3





Figure 2

3/3



a=significantly decreased vs ovx/E2 and ovx/C groups; $P < .05$.
b=significantly decreased vs sham and ovx/E2 groups; $P < .01$.

Figure 3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/00633

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 5 A61K31/40 A61K31/35

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	INTERNATIONAL JOURNAL OF CANCER vol. 43, no. 5, 1989 pages 781 - 783 N.C. MISRA ET AL. 'CENTCHROMAN-A NON-STEROIDAL ANTI-CANCER AGENT FOR ADVANCED BREAST CANCER: PHASE-II STUDY' cited in the application see the whole document ---	1-25
Y	AGENTS AND ACTIONS vol. 18, no. 5/6, 1986 pages 596 - 599 R. SRIVASTAVA ET AL. 'PROSTANOID MEDIATED EFFECTS OF CENTCHROMAN, A NON-STEROIDAL ORAL CONTRACEPTIVE' see the whole document ---	1-25
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

1 June 1994

Date of mailing of the international search report

16.06.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Hoff, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/00633

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JOURNAL OF MEDICINAL CHEMISTRY vol. 29 , 1986 pages 1801 - 1803 M. SALMAN ET AL. 'STUDIES IN ANTIFERTILITY AGENTS' see the whole document ---	1-25
Y	JOURNAL OF MEDICINAL CHEMISTRY vol. 19 , 1976 pages 276 - 279 S. RAY ET AL. 'ANTIFERTILITY AGENTS' cited in the application see the whole document ---	1-25
Y	BREAST CANCER RESEARCH AND TREATMENT vol. 10 , 1987 pages 31 - 35 V. CRAIG JORDAN ET AL. 'EFFECTS OF ANTI-ESTROGENS ON BONE IN CASTRATED AND INTACT FEMALE RATS' see the whole document ---	1-25
Y	ENDOCRINOLOGY vol. 118, no. 1 , 1986 pages 125 - 131 P.J. STEWART ET AL. 'EFFECTS OF THE ANTIESTROGENS TAMOXIFEN AND CLOMIPHENE ON BONE RESORPTION IN VITRO' see the whole document ---	1-25
Y	CALCIFIED TISSUE INTERNATIONAL vol. 36 , 1984 pages 123 - 125 P.T. BEALL ET AL. 'CLOMIPHENE PROTECTS AGAINST OSTEOPOROSIS IN THE MATURE OVARIECTOMIZED RAT' see the whole document ---	1-25
A	US,A,4 447 622 (SALMAN ET AL.) 8 May 1984 cited in the application see the whole document ---	1-25
A	EP,A,0 136 569 (TAKEDA) 10 April 1985 see the whole document -----	1-25

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 94/00633

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
REMARK: Although claims 1-24 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/US 94/00633

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4447622	08-05-84	NONE	
EP-A-0136569	10-04-85	JP-A- 60054379	28-03-85